Second Phase Of Biomedical Initiative Under Way

Singapore has completed the first phase of its Biomedical Science (BMS) initiative, and is keen to push on to phase II, which will have government investment of US$1.4bn. Under the initial plans, which ran from 2000-2005, Singapore grew its drug manufacturing output to SGD18bn (US$11.61bn), 50% higher than its target of SGD12bn (US$7.74bn). Meanwhile, eight out of the top 20 drugmakers have facilities in the country, although mainly to produce active pharmaceutical ingredients (APIs).

To read the full article, please take a trial.